Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydrazine sulfate: a current perspective.

J Gold

    Nutrition and Cancer
    |January 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Hydrazine sulfate, an anticachexia agent, combats cancer-related wasting by inhibiting gluconeogenesis. Clinical trials show it improves metabolic parameters, nutritional status, and survival with minimal side effects, suggesting its potential in cancer therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Uncaptured rates of postpartum venous thromboembolism: a US national analysis.

    BJOG : an international journal of obstetrics and gynaecology·2021
    Same author

    Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy.

    Journal of the neurological sciences·2021
    Same author

    Injectable or transdermal flunixin meglumine improves pregnancy rates in embryo transfer recipient beef cows without altering returns to estrus.

    Theriogenology·2019
    Same author

    Determination of mechanical and rheological properties of a cell-loaded peptide gel during ECM production.

    International journal of pharmaceutics·2019
    Same author

    Pharmacokinetics and pharmacodynamics of the novel monobactam LYS228 in a neutropenic murine thigh model of infection.

    The Journal of antimicrobial chemotherapy·2018
    Same author

    Pharmacokinetics and pharmacodynamics of the novel monobactam LYS228 in a neutropenic murine thigh model of infection.

    The Journal of antimicrobial chemotherapy·2018
    Same journal

    Dynamic Loss of Psoas Muscle Volume During Induction Chemotherapy Predicts Survival in Patients with Advanced Urothelial Carcinoma Receiving Avelumab Maintenance: A Multicenter Retrospective Study.

    Nutrition and cancer·2026
    Same journal

    Risk-Attributable Burden of Breast Cancer from High Red Meat Intake.

    Nutrition and cancer·2026
    Same journal

    Cultural Barriers to Early Cancer Detection in Sub-Saharan Africa: An Urgent Equity Agenda for Cancer Education.

    Nutrition and cancer·2026
    Same journal

    Associations of Whole and Refined Grain Intake with Colorectal Cancer Risk: Dose-Response and Isocaloric Substitution Analyses in a Multi-Center Population-Based Case-Control Study.

    Nutrition and cancer·2026
    Same journal

    Residential Fast-Food Exposures, Colorectal Cancer-Specific, and All-Cause Mortality: A Retrospective Study of CRC Cases from the Kentucky Cancer Registry.

    Nutrition and cancer·2026
    Same journal

    Interplay Between the Ketogenic Diet and the Gut Microbiome in Glioblastoma: A Comprehensive Review of Mechanisms and Clinical Implications.

    Nutrition and cancer·2026
    See all related articles

    Area of Science:

    • Oncology
    • Metabolic Medicine
    • Pharmacology

    Background:

    • Cancer cachexia is a complex metabolic syndrome characterized by host energy wasting.
    • Malignant processes disrupt host energy metabolism, leading to significant morbidity and mortality.
    • Effective management of cancer cachexia may impact overall disease control.

    Purpose of the Study:

    • To evaluate the efficacy and safety of hydrazine sulfate as an anticachexia agent.
    • To investigate the impact of hydrazine sulfate on host energy metabolism and cancer progression.
    • To explore the therapeutic potential of hydrazine sulfate in various cancer treatment settings.

    Main Methods:

    • Review of randomized, placebo-controlled, double-blind trials and single-arm controlled trials.

    Related Experiment Videos

  • Assessment of hydrazine sulfate's inhibitory effect on gluconeogenesis at the phosphoenolpyruvate carboxykinase (PEP CK) reaction.
  • Analysis of clinical outcomes including glucose tolerance, caloric intake, weight, appetite, performance status, pain, anorexia, laboratory indices, tumor response, and survival.

    • Main Results:

    • Hydrazine sulfate improved glucose tolerance and reduced glucose turnover.
    • The agent increased caloric intake, weight, appetite, and performance status, while decreasing pain and anorexia.
    • Observed benefits included normalization of laboratory indices, tumor stabilization or regression, and improved survival with minimal side effects.

    Conclusions:

    • Hydrazine sulfate demonstrates significant potential as an anticachexia agent by interrupting host energy wasting.
    • Its ability to improve metabolic and nutritional parameters, alongside anticancer effects, supports its use.
    • Further trials are warranted for hydrazine sulfate as a sole agent in early drug-resistant cancer, in combination therapies, or with parenteral nutrition.